Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244881 | 0.83 | ROCK1 (0.40) | — | |
| SCHEMBL3247390 | 0.82 | GRIN2B (0.39) | LMNAKDM4EALDH1A1 | |
| SCHEMBL3128413 | 0.82 | KDM4E (0.36) | LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL3239090 | 0.81 | GRIN2B (0.41) | LMNAKDM4EALDH1A1 | |
| SCHEMBL3240895 | 0.80 | TAAR1 (0.43) | KDM4EALDH1A1MAPTGAA | |
| SCHEMBL27138647 | 0.76 | PARK7 (0.46) | ALDH1A1MAPTGAA | |
| SCHEMBL30062474 | 0.76 | PARK7 (0.46) | ALDH1A1MAPTGAA | |
| SCHEMBL3248520 | 0.74 | HDAC1 (0.38) | ALDH1A1MAPTGAA | |
| SCHEMBL3245592 | 0.72 | ALDH1A1 (0.37) | KDM4EALDH1A1MAPTGAA | |
| SCHEMBL3246489 | 0.71 | CYP11B2 (0.36) | LMNAKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010008777-A2 | FUSED AZABICYCLIC PYRIDINES | LIGAND PHARMACEUTICALS INC. (US) | 2010-01-21 | — | — | WO | disclosed |